Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Ayurcann Holdings Corp

Healthcare US AYURF

0.002USD
0.00(0%)

Last update at 2026-06-02T20:00:00Z

Day Range

0.010.01
LowHigh

52 Week Range

0.0020.03
LowHigh

Fundamentals

  • Previous Close 0.002
  • Market Cap0.39M
  • Volume2500
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.99705M
  • Revenue TTM31.28M
  • Revenue Per Share TTM0.16
  • Gross Profit TTM 8.62M
  • Diluted EPS TTM-0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -3.48578M -3.96773M -5.30713M -1.72779M 0.06M
Minority interest - - - - -
Net income -3.48578M -3.96774M -5.30713M -3.08791M -0.27836M
Selling general administrative 12.02M 10.53M 8.22M 5.51M 2.46M
Selling and marketing expenses - - - - -
Gross profit 10.16M 8.47M 3.68M 3.92M 4.63M
Reconciled depreciation 0.98M 1.24M 0.78M 0.32M 0.28M
Ebit - - - -3.33221M 2.16M
Ebitda - - - -1.31585M 0.65M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -2.45836M -2.78978M -4.99108M -1.59912M 2.16M
Other operating expenses - - - - -
Interest expense 0.66M 0.72M 0.03M 0.09M 0.32M
Tax provision - - 0.00000M -0.33545M 0.34M
Interest income - - - - -
Net interest income -0.66277M -0.71686M -0.03019M -0.09115M -0.31518M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - -0.33545M 0.34M
Total revenue 31.11M 25.16M 12.49M 11.08M 7.63M
Total operating expenses 33.57M 27.95M 17.48M 12.68M 5.47M
Cost of revenue 20.95M 16.69M 8.81M 7.17M 3.01M
Total other income expense net -0.36465M -0.46110M -0.28585M -0.03753M -1.78704M
Discontinued operations - - - - -
Net income from continuing ops -3.48578M -3.96773M -5.30713M -1.39234M -0.27836M
Net income applicable to common shares - - - -3.08791M -0.27836M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 12.68M 14.85M 12.73M 7.28M 6.68M
Intangible assets 1.20M 1.75M 2.30M - -
Earning assets - - - - -
Other current assets - - - - -
Total liab 15.63M 14.32M 10.04M 2.39M 1.93M
Total stockholder equity -2.95091M 0.53M 2.69M 4.89M 4.75M
Deferred long term liab - - - - -
Other current liab - - - - 0.34M
Common stock - - - 8.05M 5.79M
Capital stock 12.95M 12.95M 11.16M 8.05M 5.79M
Retained earnings -17.86481M -14.37903M -10.41129M -5.10416M -2.01625M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 1.99M 0.39M 0.97M 1.35M 0.73M
Cash and equivalents - - - - -
Total current liabilities 15.09M 13.60M 9.98M 2.17M 1.57M
Current deferred revenue - - - - -
Net debt - - - - -
Short term debt - - - - -
Short long term debt 0.04M 0.04M - - -
Short long term debt total - - - - -
Other stockholder equity - - - 0.94M 0.13M
Property plant equipment - - - 1.19M 1.25M
Total current assets 10.21M 11.50M 9.27M 6.09M 5.43M
Long term investments - - - - -
Net tangible assets - - - 4.89M 4.75M
Short term investments - - - - -
Net receivables 3.96M 5.24M 4.84M 1.54M 2.08M
Long term debt 0.09M 0.13M - 0.04M 0.04M
Inventory 3.72M 5.36M 3.28M 2.95M 2.32M
Accounts payable 3.33M 4.17M 2.07M 0.91M 1.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 2.46M 3.36M 3.46M 1.19M 1.25M
Capital lease obligations 0.59M 0.73M 0.18M 0.32M 0.44M
Long term debt total - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -0.09253M -0.43794M -0.29738M -0.26262M 0.36M
Change to liabilities - - - 0.91M 0.95M
Total cashflows from investing activities - - - -0.26262M 0.36M
Net borrowings -0.68261M -0.04803M - -0.18469M -0.27449M
Total cash from financing activities -0.68261M -0.04803M 0.19M 0.94M 0.54M
Change to operating activities - - - -0.02411M -0.32035M
Net income -3.48578M -3.96774M -5.30713M -3.08791M -0.27836M
Change in cash 1.60M -0.58287M -0.38286M 0.63M 0.70M
Begin period cash flow 0.39M 0.97M 1.35M 0.73M 0.02M
End period cash flow 1.99M 0.39M 0.97M 1.35M 0.73M
Total cash from operating activities 2.37M -0.09689M -0.27130M -0.05009M -0.19856M
Issuance of capital stock - - 0.00000M 1.39M 0.77M
Depreciation 0.98M 1.24M 0.78M 0.32M 0.28M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory 1.64M -2.08552M -0.32918M -0.63092M -2.03503M
Change to account receivables 1.27M -0.39464M -3.79307M 0.66M -1.70912M
Sale purchase of stock - 0.00000M -0.02047M -0.26066M -
Other cashflows from financing activities - - - - 0.04M
Change to netincome - - - 2.15M 2.30M
Capital expenditures 0.09M 0.44M 0.30M 0.26M 0.51M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 4.77M 2.16M 2.34M 0.58M -2.77991M
Stock based compensation 0.00000M 0.41M 1.53M 2.11M 0.13M
Other non cash items 0.11M 0.07M 0.03M 0.03M 2.44M
Free cash flow 2.28M -0.53484M -0.56867M -0.31271M -0.70755M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AYURF
Ayurcann Holdings Corp		 - -% 0.002 - - 0.01 2.70 0.06 -1.0548
ZTS
Zoetis Inc		 1.20 1.57% 77.59 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 0.58 1.91% 31.01 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 153.91 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 -0.79 1.89% 40.92 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Ayurcann Holdings Corp. provides post-harvest outsourcing solutions to licensed cannabis producers in Canada. The company offers extraction, processing, and co-manufacturing of pharma grade cannabis to produce various derivative cannabis products in the medical and recreational markets. It also manufactures and distributes cannabis products. The company sells product under the Fuego, H&S, and XPLOR brand names. Ayurcann Holdings Corp. is headquartered in Pickering, Canada.

Ayurcann Holdings Corp

1080 Brock Road, Pickering, ON, Canada, L1W 3X4

Key Executives

Name Title Year Born
Mr. Igal Sudman Co-Founder, Corp. Sec., CEO & Chairman NA
Mr. Buzaker Roman Co-Founder, Pres, CFO, COO & Director NA
Mr. Raj Virk Head of Quality & Compliance NA
Mr. Igal Sudman Co-Founder, Corporate Secretary, CEO & Chairman NA
Mr. Buzaker Roman Co-Founder, President, COO & Director NA
Mr. Yisroel Zuchter Chief Financial Officer NA
Mr. Roman Buzaker Co-Founder, President, COO & Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.